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【Abstract】

Schizophrenia is a chronic, recurrent and disabling psychotic disorder. Improving patients'

adherence and preventing relapse are key points in the treatment of schizophrenia, as well as the core factors to
determine patients' prognosis and social function recovery. Long-acting injectable (LAI) is an important treatment
strategy and recurrent prevention of schizophrenia, which is recommended by guidelines/consensus as one of the
preferred treatment methods for the all schizophrenia. At the same time, community as an important site for the
rehabilitation of schizophrenia, some community management models have been carried out recently. At present, a
series of policies and documents stressed the application of LAI in the management of schizophrenia in community.
However, some community mental health workers are lack of experience and application skills of LAI, which
affects the application of LAI in the community and become one of the bottlenecks for the rehabilitation of patients.
Therefore, under the organization of the Chinese Schizophrenia Coordination Group and Chinese Society of
General Practice, 13 experts formed the expert group members of this consensus, which based on the
evidence-based medical suggestion, domestic and international guidelines and consensus, experts experience and
the characteristics of Chinese community. In order to solve medical problems in the community LAI application
and improve the compliance and prognosis of schizophrenia of patients.
【Key words】 Schizophrenia; Antipsychoric agents; Long-acting injectable; Community health services
【Chinese Library Classification Number】R 749.3 【Document Identification Code】A
1 Overview
1.1 Unmet needs and challenges of schizophrenia Schizophrenia is a chronic, recurrent, and highly disabling psychotic
disorder that often onsets at youth/prime age and shows a repeatedly fluctuating course. Among them, 10%–15% recover from
the first episode of schizophrenia, while a higher proportion may enter a protracted state of aggravation [1-3]. Relapse refers to
not only the re-appearance of psychiatric symptoms, but also the acceleration of disease progression, the reduction of patient
response to drug therapy, and the effects on patients' function and quality of life; it is associated with the changes in brain
morphology and structure, resulting in a decrease in patients' gray matter [4-8] and further exacerbation of their poor prognosis.
According to the findings by ROBINSON et al. [2] after following up 104 patients with first-episode schizophrenia, 82%
had at least one relapse within 5 years, and discontinuation was the most potent predictor of relapse — discontinuers had a
5-fold higher risk of relapse than those who continued the drug therapy; another systematic review of 6 studies showed that
after discontinuation, 77% of patients relapsed within 1 year and 90% relapsed after 2 years. In contrast, patients with good
treatment compliance had only an 18% risk of relapse.
Therefore, standard maintenance therapy with antipsychotics is a key factor in the prevention of schizophrenia relapse and a
core factor to determine the prognosis and social function inpairment of patients[9].
1.2 Characteristics and status in therapy of long-acting injectables Long-acting injectables are generally esterified from
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antipsychotics. For most long-acting injectables, active ingredients are commonly stored at the injection site and slowly
absorbed into the circulatory system after intramuscular or subcutaneous injection, thereby ensuring stable plasma
concentrations in patients and reducing the risk of relapse and adverse reactions

[10-11]

. Long-acting injectables offer more

merits over oral drugs: If patients delayed the injection in the clinic, clinicians can be aware of their non-compliance, which
will be helpful to reduce the medication-related burden, and shorten intentional or unintentional window period, as well. [10].
Compared with first-generation antipsychotics, atypical antipsychotics improve motor function, neurocognitive function
and neuroendocrine tolerance with broader targets; long-acting injectable atypical antipsychotics further integrate the merits
of new antipsychotics and long-acting injectables, bringing more benefits to patients [12].
As one of the important ways in the treatment of schizophrenia and prevention of relapse, long-acting injectables are
recommended by the American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia
(APA), the Schizophrenia Practice Guideline of the German Society of Psychiatry, Psychotherapy and Psychosomatics
(DGPPN), the Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for the Management
of Schizophrenia and Related Disorders (RANZCP), the Psychosis and Schizophrenia in Adults: Treatment and Management
Guideline (updated version) by the National Institute for Health and Care Excellence (NICE), the World Federation of
Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia (WFSBP) and the Expert Consensus
on Long-acting Injectables in China

[13-15]

. Extensive data have shown that treatment with long-acting injectables can

significantly reduce the risk of re-admission, delay relapse, and reduce the risk of relapse over a longer period even after
discontinuation [16-18]. Furthermore, it has been shown that the second-generation antipsychotics have neuroprotective effects
such as enhancing nerve regeneration, increasing neurotrophic factor levels, preventing/reversing dendritic spine loss and
oligodendrocyte injury, and preventing β-amyloid and hydrogen peroxide-induced cell death [19].
The commonly used first-generation long-acting injectable antipsychotics include Fluphenazine Decanoate and Haloperidol
Decanoate. The second-generation long-acting injectable antipsychotics marketed in China include Risperidone Long-acting
Injectable (RLAI), Paliperidone Palmitate 1-month (PP1M) and Paliperidone Palmitate 3-month (PP3M) [9, 15].
1.3 Status of community management of schizophrenia and application of long-acting injectables Since patients with mental
disorders in communities are characterized by poor insight, low rates in regular medication regular medication rate, high
therapy interruption rate, high relapse rate, high disability rate and high risk of causing accidents, countries/regions are
exploring measures to reduce the risk of relapse and the rate of therapy interruption, and improve patient treatment
compliance. In the past 10 years, long-acting injectables have been widely used in communities in Canada, Australia, the
United States and other countries/regions for patients with severe mental disorders, showing that they can improve patients’
treatment compliance and social function, and reduce violence and re-admission rate.
In China, patients with schizophrenia receive consolidation and maintenance treatments mainly at community health
institutions. By the end of 2020, about 6.43 million patients with severe mental disorders received treatment and management
in communities, of which 71.28% had schizophrenia with a medication rate of 88.74% and a regular medication rate of
70.00%, higher than those in 2017 and 2018. However, there was a significant difference between East China and West China:
The medication rate and regular medication rate in West China were still significantly lower than those in East and Central
China, and the regular medication rate in Yunnan Province, Tibet Autonomous Region, Gansu Province and Qinghai Province
was still less than 50% [20-22].
Within the world, long-acting injectables are widely used in communities for the intervention of schizophrenia. Recently,
China has successively carried out a series of exploration activities of community management models, and actively promoted
the use of long-acting injectables in communities to improve patient medication compliance. Several management policies
and documents in China have emphasized the use of long-acting injectables in the management of schizophrenia in
communities. For example, the Standards for the Management and Treatment of Severe Mental Disorders (2018 Edition)
issued by the National Health Commission of the People's Republic of China recommends the use of long-acting injectables
for patients with poor treatment compliance, those under weak or under no home monitoring and those with the risk of causing
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accidents

[23]

. Since then, all provinces in China have formulated policies to recommend the use of long-acting

injectables. For example, the Construction and Development Plan for the Mental Health System in Shanghai
(2020-2030) issued by eleven departments including the Shanghai Municipal Health Commission and Shanghai
Municipal Development & Reform Commission points out to promote the use of long-acting injectables in patient
management during their follow-up, improve the community-based involuntary follow-up management system, and
specify the responsibilities of public security bureaus, sub-districts (townships), medical institutions and guardians in
patient management during regular outpatient follow-up and community follow-up[24]. Districts in Beijing support the
development of community management models during the COVID-19 pandemic [23, 25–26] and provide free treatment
with long-acting injectables for patients with severe mental disorders at home who have poor treatment compliance and
who are under weak or under no home monitoring. Guangdong Province included the promotion of long-acting
injectables in its key work plan for mental health in 2020, encouraged all regions to actively coordinate with relevant
departments, and issued an "Implementation Plan for the Use of Long-acting Injectables in Patients with Schizophrenia"
to improve the poor medication compliance in high-risk patients who did not take medications or who were under no
(weak) monitoring, and reduce the occurrence of accidents [27].
However, long-acting injectables are currently prescribed at a low rate. A study on the application mode of long-acting
injectables in the treatment of schizophrenia in 15 Asian countries/regions in 2020 pointed out that the usage rate of
long-acting injectables was only 0.66% in China, far below the average of the 15 countries/regions (17.9%) [28]; in addition,
the data from a sampling survey for communities in Beijing in 2021 showed that the prescription rate of long-acting
injectables was 2.4% [29]. Meanwhile, due to limited clinical knowledge and experience of community mental health
workers, there remains a large unmet need in the choice of long-acting injectables and the handling of related problems.
1.4 Top ten critical clinical issues in the use of long-acting injectables in communities: In order to satisfy unmet needs and
manage patients with schizophrenia in communities more efficiently, the expert group of this consensus collected/summarized
medical issues (a total of 10 issues) in frontline clinical practice through in-depth communications with community mental
health workers in the typical communities where schizophrenia management is being carried out, so as to provide targeted
answers to the questions of community physicians.
Issue 1: Which patients with schizophrenia are eligible for the use of long-acting injectables?
Issue 2: What are the assessment indicators and considerations before the use of long-acting injectables in community
patients?Issue 3: What is the experience of switching to/using long-acting injectables in patients with different medication
histories?Issue 4: What are the benefits of using longer-interval injectables in patients and what are the intended populations
and treatment switching methods?Issue 5: What are the precautions for the use of long-acting injectables in special
populations?Issue 6: What are the common adverse reactions during the use of long-acting injectables and how to deal with
them?Issue 7: What are the management measures for symptom fluctuations during the use of long-acting injectables?Issue 8:
What are the principles and precautions for combination therapy during the use of long-acting injectables?Issue 9: Under what
circumstances do community mental health workers need support from psychiatrists?Issue 10: What are the main points the
community mental health workers should convey when recommending long-acting injectables for patients?
2 Method of Consensus Formulation
Under the organization of Chinese Schizophrenia Coordination Group, Chinese Society of Psychiatry, in conjunction
with the Chinese Society of General Practice, an expert group was set up with 13 experts in psychiatry and general practice to
formulate the Expert Consensus on Long-acting Injectable Antipsychotic in the Treatment of Schizophrenia in Community
(hereinafter referred to as the consensus). The expert group systematically retrieved a total of 1,108 articles in both Chinese
and English from PubMed, CNKI, Wanfang Data and VIP with such keywords as "antipsychotic OR neuroleptic",
"schizophrenia" and "depot OR long acting OR microsphere OR decanoate OR palmitate OR enanthate" from January 2010 to
June 2022. During this process, the expert group discussed the direction of content drafting and consensus opinions in two
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rounds of expert consensus meeting. In the first round of meeting, the experts analyzed 10 hot topics collected to determine the
main direction and key information of the consensus. According to the consensus opinions on common problems in
communities, the articles were further screened to eliminate duplicates, retracted articles, case reports-related articles, animal
experiments-related articles, articles in which original texts were unavailable, and articles irrelevant to the 10 issues. A total of
33 articles were finally screened
included

[16-19, 30-58]

and 13 domestic and foreign authoritative guidelines and consensuses were

[9, 14, 59-69]

. Combined with the evidence-based data summarized from relevant articles, the second round of meeting

will present existing research data and recommendations for relevant issues.
In the consensus, the Levels of Evidence and Grades of Recommendations system developed by the Oxford Centre for
Evidence-Based Medicine (OCEBM) and updated in 2009 is used to classify evidence into 5 levels (1–5 levels) and
recommendations into A–D grades (from strong to weak), as shown in Table 1.
Table 1 Level of Evidence Graded by the OCEBM
Grade
of Level
of Etiology, Treatment and Prevention
Recommendation Evidence
A
1a
Systematic review of several homogeneous randomized controlled studies
1b
Individual randomized controlled studies (with a narrow confidence interval)
1c
All case or no case studies (all or part of patients died before treatment; only part of
patients died or all survived after treatment)
B
2a
Systematic review of homogeneous cohort studies
2b
Individual cohort studies (including low-quality randomized controlled studies, e.g.,
follow-up rate < 80%)
2c
Outcome studies: ecological studies
3a
Systematic review of homogeneous case-control studies
3b
Individual case-control studies
C
4
Case series report studies, and low-quality cohort and case-control studies
D
5
Expert opinions not critically evaluated or based entirely on physiological and
fundamental studies
3 Evidence-based Expert Consensus on the Application of Long-acting Injectables in the Treatment and Management
of Patients with Schizophrenia in Communities
3.1 Which patients with schizophrenia are eligible for the use of long-acting injectables?
[Recommendation]
Long-acting injectables are recommended at all stages of schizophrenia, and the earlier they are used, the more
benefits patients may have. (Recommendation grade: A)
After decades of evidence accumulation, long-acting injectables have been validated to be consistently effective in
patients at all stages of schizophrenia. Therefore, multiple guidelines and consensuses recommend long-acting injectables for
patients at all stages of schizophrenia, those with poor or uncertain compliance and voluntarily choose long-acting injectables.
In addition, a number of guidelines emphasize the use of long-acting injectables in the early course of schizophrenia [9, 14, 59, 61–
63, 65, 68, 70–71]

. For example, the Recommendations for Long-acting Injectable Antipsychotics in Canada

Consensus on Long-acting Injectables in the Treatment of Schizophrenia in Taiwan (China)

[63]

[65]

and the Expert

recommend the use of

long-acting injectables at all stages of schizophrenia; the Expert Consensus on Long-acting Injectable Antipsychotic in the
Treatment of Schizophrenia in China [9] recommends that second-generation long-acting injectable antipsychotics can be used
as first-line treatment for patients with first-episode, early-phase, acute-phase and maintenance-phase schizophrenia, and
first-generation long-acting injectable antipsychotics can be considered as second-line treatment for patients with acute-phase
schizophrenia.
Once schizophrenia is diagnosed, the earlier long-acting injectables are used, the more benefits patients may have

[30]

.

Long-acting injectables are therefore recommended at all stages of schizophrenia.
3.1.1 First-episode schizophrenia: The First Episode Psychosis Intervention Program (CRUPEP) found that first-episode
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schizophrenia patients treated with long-acting injectables (PP1M and PP3M) had greater improvement in symptoms
(PP1M/PP3M versus oral medication, P < 0.001) [31]; another randomized controlled study showed that PP1M significantly
improved the score of Positive and Negative Syndrome Scale (PANSS) in unmedicated patients with first-episode
schizophrenia [32].
3.1.2 Early-phase schizophrenia: Data from several studies assessing long-acting injectables in patients with early-phase
schizophrenia (course of disease < 3 years) have shown that long-acting injectables can significantly improved clinical and
functional outcomes, minimize the risk of relapse, and reduce medical costs [33–35].
3.1.3 Acute-phase schizophrenia: A study of PP1M in Chinese population with acute-phase schizophrenia showed that after
13 weeks of treatment, patient compliance increased from 34.7% at baseline to 71.5%, and 72.6% of patients achieved
clinically significant improvement in their PANSS scores (30% improvement)

[36]

. Another study followed up patients who

were acutely admitted due to recurrent schizophrenia for 6 weeks, and found that PP1M monotherapy or PP1M + oral
medication can significantly reduce the score of Clinical Global Impression-Severity (CGI-S) in these patients on day 8, and
significantly improve the scores of Brief Psychiatric Rating Scale (BPRS) and Personal and Social Performance Scale (PSP)
at week 6 [37].
3.1.4 Maintenance-phase schizophrenia: A 2-year study showed that long-term use of PP1M was effective in reducing the risk
of relapse by nearly 30% compared with oral antipsychotics

[38]

significantly increased in patients who used PP1M for 2 years

[39]

. Additional studies showed that employment rates can be
.

A meta-analysis of real-world studies found that more patients achieved better compliance following treatment with
long-acting injectables [80%, OR = 1.89, 95% CI (1.52, 2.35)], compared to oral medications [40].
3.2 What are the assessment indicators and considerations before the use of long-acting injectables in community patients?
[Recommendation]
(1) Assessment indicators before use include routine vital signs, physical illness, and potential medication-related
adverse reactions. (Recommendation grade: A)
(2) Before use, the clinical characteristics of patients, adverse reactions of long-acting injectables and injection
characteristics should be taken into comprehensive consideration. (Recommendation grade: B)
3.2.1 Assessment indicators before use of long-acting injectables: APA and Chinese guidelines propose the following [14-15]:
Baseline assessment before the use of antipsychotics is mainly to monitor the vital signs and physical illness of patients,
including height, body mass, hematology, liver and kidney functions and female pregnancy test; before the use of
antipsychotics, potential medication-related adverse reactions should also be assessed, along with disease-related family
history, such as metabolic disorders and cardiovascular risks; the process and results of previous therapeutic medication
(dosage, duration, efficacy, adverse reactions and compliance) should be understood; if it is decided to use long-acting
injectables, the selection of long-acting injectables is similar to that of oral drugs, considering the previous treatment response,
tolerance, pharmacology and adverse reactions, along with potential specific preferences of patients related to the frequency,
type and site of injection; due to the limitations of community health care institutions in staffing and medical equipment, the
assessment indicators before the use of long-acting injectables should be adjusted according to local conditions; during the
assessment of patients before the selection of treatment regimens, if they are found to have a risk of causing accidents or
criminal events or to be under weak monitoring, it is recommended to give priority to long-acting injectables.
3.2.2 Considerations for selection of long-acting injectables recommended by consensuses: The characteristics, usage and
dosage of long-acting injectables marketed in China are shown in Tables 2 and 3.
The 2020 Chinese Expert Consensus proposes that the following factors need to be considered when switching to
long-acting injectable antipsychotics from oral antipsychotics: clinical characteristics and current efficacy of patients; dosage
and treatment duration of the oral drug currently taken; pharmacodynamic and pharmacokinetic profiles of the oral drug and
the target long-acting injectable to be used [9]. Combined with the realities of antipsychotic treatment in China, easy-to-use,
longer-interval long-acting injectables supported by sufficient evidence-based data from domestic patient population are
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recommended. Considerations for the selection of long-acting injectable antipsychotics recommended by consensuses are
shown in Table 4.
Table 2 Characteristics, Usage and Dosage of Long-acting Injection of First-generation Antipsychotics in China [9]
Item

Haloperidol
Decanoate

Fluphenazine Decanoate

Indication (in China)

Maintenance
treatment
psychosis

Injection site

Intramuscular
injection

Intramuscular injection

Starting dose

50 mg

12.5~25.0 mg

Maintenance dose

50~100 mg; 300 12.5~100.0 mg
mg a

Injection frequency

Once
weeks

Whether supplemental oral
medication is required for
initial treatment b

No

No

Whether
injection
re-preparation is required c

Yes

Yes

Whether refrigerated storage
is required d

No

No

Whether
post-injection
observation is required e

No

No

Acute/chronic schizophrenia; relieving apathy and withdrawal
of symptoms in simple and chronic schizophrenia; also applicable to
those who refuse medication and those who need long-term medication
for maintenance treatment

every

4 Not specified in the package insert

Notes:
a

The dose for the treatment of schizophrenia is 50–100 mg in the Haloperidol Decanoate Package Insert approved by the Food and Drug Administration (FDA), but

the maximum dose mentioned in articles can be up to 300 mg/4 weeks [41]; b Whether oral drugs with the same active ingredients as long-acting injectables need to be
taken during the initial treatment with long-acting injectables according to the pharmacokinetic profiles and degree of drug release of the injectables so as to ensure
that the drug concentration is within the therapeutic concentration range; c Whether the injection needs to be prepared before administration (dissolve the active
ingredients in a special solvent and transfer to a syringe);

d

Whether the injection needs to be stored in a refrigerator; e Whether the FDA has a requirement of

observation following the administration

Table 3 Characteristics, Usage and Dosage of Long-acting Injection of the Second Generation of Domestic Antipsychotic
Drugs [9, 72]
Item

RLAI

Indication (in China)

Acute/chronic schizophrenia and other Acutepsychotic states with apparent positive or maintenance-phase
negative symptoms. Affective symptoms schizophrenia
associated with schizophrenia

Injection site

Deltoid/gluteus

Deltoid (the
doses)/gluteus

Starting dose

25.0 mg

1st dose: 150 mg eq a; 2nd 3.5 times the last PP1M
dose: 100 mg eq
dose

Maintenance dose

25 mg (up to 50 mg)

75 mg eq (25–150 mg eq) 175~525 mg eq

Injection frequency

Once every 2 weeks

Once a month (1 week Once every 3 months
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st

between the 1 and 2nd
doses)
Whether supplemental No
oral
medication
is
required
for
initial
treatment b

No

No

Whether
injection Yes
re-preparation
is
required c

No

No

Whether
refrigerated Yes
storage is required d

No

No

Whether post-injection No
observation is required e

No

No

Notes: RLAI = Risperidone Long-acting Injectable, PP1M = Paliperidone Palmitate 1-month, PP3M = Paliperidone Palmitate 3-month;
a

The dose is calculated as paliperidone, and paliperidone equivalent is in mg eq;

b

Whether oral drugs with the same active ingredients as long-acting injectables need to be taken during the initial treatment with long-acting injectables according to

the pharmacokinetic profiles and degree of drug release of the injectables so as to ensure that the drug concentration is within the therapeutic concentration range; c
Whether the injection needs to be prepared before administration (dissolve the active ingredients in a special solvent and transfer to a syringe); d Whether the injection
needs to be stored in a refrigerator; e Whether the FDA has a requirement of observation following the administration

Table 4 Factors to be Considered When choosing Long-term Antipsychotic Injection Therapy
Considerations

Selection of Long-acting Injectables

Clinical characteristics of
patients (e.g., in acute
exacerbation)

Long-acting injectables that do not require supplemental oral medication during the initial
treatment are recommended (e.g., PP1M) for higher convenience and compliance;
Long-acting injectables supported by sufficient acute-phase treatment data are
recommended (e.g., PP1M ).

Adverse
reactions
long-acting injectables

of

PP1M, Risperidone Long-acting Injectable, and Aripiprazole Long-acting Injectable should
be considered instead of Olanzapine Long-acting Injectable if patients are concerned about
metabolism-related adverse reactions.

Injection characteristics of
long-acting injectables

Long-acting injectables that do not require supplemental oral medication during the initial
treatment (e.g., PP1M and Olanzapine Long-acting Injectable) can be considered if patients
are relatively concerned about the convenience of injections;
Long-acting injectables that do not require observation after injection (e.g., PP1M,
Risperidone Long-acting Injectable, and Aripiprazole Long-acting Injectable);
Long-acting injectables available in multiple strengths, and given at adjustable therapeutic
doses according to patient characteristics;
Long-acting injectables that do not require refrigerated storage or injection preparation;
Longer-interval long-acting injectables

3.3 What is the experience of switching to/using long-acting injectables in patients with different medication histories?
[Recommendation]
Patients who have previously used an oral drug with the same molecule as the long-acting injectable to be taken
should switch to the long-acting injectable according to the appropriate package insert, either a crossover approach or
a tentative combination of the two according to the control of symptoms; if they have not used an oral drug with the
same molecule, a tolerance test is usually recommended (Recommendation grade: C).
The 2020 APA Guideline points out that if patients plan to start treatment with a long-acting injectable, a tolerance test
with the oral antipsychotic with the same molecule is usually performed; the dose for switching from different oral
medications to the corresponding long-acting injectables and the necessity for concomitant oral medications are usually
described in the package inserts [14]. The 2020 Chinese Expert Consensus emphasizes that when patients consider switching
from oral medication to a long-acting injectable, if a long-acting injectable is available for the oral medication, patients can
switch drugs by referring to the usage and dosage in the package insert of the long-acting injectable, while if no long-acting
7 / 24
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injectable is available for the oral medication, another long-acting injectable should be selected against the clinical
characteristics of patients; for patients in the acute phase, long-acting injectables that do not require supplementary oral
medication during the initial treatment (e.g., PP1M) should be considered for higher treatment convenience and patient
compliance; long-acting injectables supported by sufficient acute-phase treatment data (e.g., PP1M) should be considered [9].
Due to the differences in the tolerance and sensitivity to antipsychotics among patients, appropriate initial treatments
with long-acting injectables should be selected according to the conditions of patients.
3.3.1 First-episode unmedicated patients: This is a special category of patients in the early course of the disease. Physicians,
patients and their families have higher expectations of their prognosis, and first-episode patients will benefit more from
long-acting injectables. However, such patients are more sensitive to treatment. Physicians need to consider their sensitivity
when giving long-acting injectables, carefully select the dose and timely deal with adverse reactions [73].
3.3.2 Patients already taking antipsychotics and patients switching to long-acting injectables or relapsed after discontinuation
of previous medications: Such patients who have never used oral medications with the same molecule as long-acting
injectables need to receive a tolerance test first. It is recommended that oral medications should be taken at the lowest
therapeutic dose, and the duration of the tolerance test may be considered as 5 half-lives of oral medications.
The molecular tolerance test of different drugs for long-acting injectables in domestic market is shown in Table 5.
Equivalent dose data of different long-acting injectables and various oral antipsychotics are shown in Table 6.
Table 5 Molecular Tolerance Test of Different Drugs for Long-acting Injection in Domestic Market [72, 74]
Long-acting
Dose under Tolerance Test
Duration
of Half-life of Oral Drug
Injectable
Tolerance Test
Haloperidol
For Haloperidol Decanoate and Fluphenazine Decanoate, —
—
Decanoate
the tolerance and dosage are recommended to be
determined with their corresponding short-acting dosage
Fluphenazine
forms prior to injection [75-76]
Decanoate
RLAI
Risperidone Tablets 2–4 mg/d
7d
Risperidone: 3 h
PP1M
Paliperidone Extended-Release Tablets, 6 mg/d
4~6 d
Paliperidone: 24 h
Note: - N/A
Table 6 Equivalent Dose Data of Different Long-acting Injections and Various Oral Antipsychotics [42-44, 51, 73]
Drug

Low Dose

Medium Dose

High Dose

Haloperidol
Decanoate

50 mg/4 weeks

100 mg/4 weeks

150–200 mg/4 weeks

Fluphenazine
Decanoate

12.5
weeks

25–37.5
weeks

50–75 mg/4 weeks

Reference Dose

RLAI
Paliperidone
Palmitate

mg/4

mg/4

25 mg/2 weeks

37.5 mg/2 weeks

50 mg/2 weeks

75 mg/4 weeks

100 mg/4 weeks

150 mg/4 weeks

First-generation oral antipsychotics (FGAs)
Chlorpromazine

100 mg

200-300 mg

400-600 mg

Fluphenazine

2-6 mg

12-24 mg

30 mg

Haloperidol

2-4 mg

10-20 mg

40 mg

Perphenazine

10 mg

20-40 mg

60 mg

Sulpiride

200-400 mg

500-800 mg

1,000-1,200 mg

Second-generation oral antipsychotics (SGAs)
Paliperidone ER
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Risperidone

2 mg

4mg

6 mg

Olanzapine

5 mg

10-15 mg

20 mg

Amisulpride

400 mg

400-800 mg

1,000-1,200 mg

Aripiprazole

10-15 mg

20-25 mg

30 mg

Clozapine

200 mg

300-400 mg

600 mg

Lurasidone

40 mg

40-80 mg

80 mg

Quetiapine

400-600 mg

500-600 mg

800 mg

Ziprasidone

80-120 mg

120 mg

160 mg

Note: 100 mg Chlorpromazine is approximately equivalent to 1.5 mg Risperidone and all data have been rounded.

3.3.3 Take Paliperidone Palmitate which is now commonly used in communities as an example [73]
3.3.3.1 Switching from previous oral Paliperidone Extended-Release Tablets or Risperidone to Paliperidone Palmitate
Switching method: In this case, immediate discontinuation of oral medication and injection of Paliperidone Palmitate on
the following day may be considered; discontinuation may also be carried out using a crossover approach at a faster rate.
However, if patients are in the acute phase, especially those receiving higher doses, immediate or excessively rapid
discontinuation should be avoided as much as possible to prevent symptom fluctuations.
Dose for switching: Prior to switching to Paliperidone Palmitate from oral Risperidone or Paliperidone
Extended-Release Tablets, a dosing regimen that delivers conventional loading dose (day 1: 150 mg; day 8: 100 mg) with the
route of deltoid injection is recommended.
3.3.3.2 Switching from other oral antipsychotics to Paliperidone Palmitate: In patients who have not previously used
paliperidone, it is recommended to receive a tolerance test with Paliperidone Extended-Release Tablets 6 mg/d orally for 4–6
days.
Switching method: Since most oral antipsychotics have a half-life of less than 3 days, Paliperidone Palmitate should be
given at the recommended loading dose (day 1: 150 mg; day 8: 100 mg). Original oral drugs should be tapered; for example,
oral Aripiprazole, Ziprasidone, Amisulpride, or other conventional drugs are recommended to be tapered and discontinued in
1–2 weeks. Oral drugs with strong sedative and/or anticholinergic effects, such as Clozapine, Olanzapine or Quetiapine, are
recommended to be switched using a crossover approach over a longer period, generally 2–4 weeks; Clozapine may take a
longer period, and sometimes even a long-term low-dose combination is required.
Dose for switching: There is a lack of data on equivalent doses between Paliperidone Palmitate and oral antipsychotics
other than Risperidone and Paliperidone. Generally, the dose for switching can be converted from the equivalent doses of low,
medium and high doses of different drugs and adjusted as appropriate. The switching is recommended to be performed under
the guidance of professional medical institutions or specialists.
3.3.3.3 Switching from RLAI or other long-acting injectable antipsychotics to Paliperidone Palmitate
Switching method: Patients previously treated with RLAI or other conventional long-acting injectables may be switched
directly to Paliperidone Palmitate at the corresponding dose in the next injection without the need for a loading dose. If
symptom fluctuations occur during the switching, a tentative combination with oral drugs such as Paliperidone
Extended-Release Tablets and Risperidone Tablets can be considered.
Dose for switching: The monthly dose of Paliperidone Palmitate is twice the dose of RLAI. The injection dose of 25 mg
every 2 weeks for RLAI is equivalent to the dose of 50–75 mg eq every month for Paliperidone Palmitate, the injection dose of
37.5 mg every 2 weeks for RLAI is equivalent to the dose of 75–100 mg eq every month for Paliperidone Palmitate, and the
injection dose of 50 mg every 2 weeks for RLAI is equivalent to the dose of 100–150 mg eq every month for Paliperidone
Palmitate.
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During the switching of drugs or at the early stage following switching completion, the symptom fluctuations and
adverse reactions should be observed in patients. Prolonging the time of cross-medication of the two drugs as appropriate is
conducive to successful switching. In case of serious adverse reactions, professional assessment and treatment should be
performed in a timely manner.
3.4 What are the benefits of using longer-interval injectables in patients and what are the intended populations and treatment
switching methods?
[Recommendation]
Switching to longer-interval injectables for patients in stable condition helps to improve their compliance and
outcomes, and reduce the rate of relapse and burden of care; patients should be monitored regularly when they use
longer-interval injectables (e.g., ≥ 1 month). (Recommendation grade: A)
The 2021 Expert Consensus on Long-acting Injectables in Taiwan Region mentions that [63] patients in stable condition
can switch from long-acting injectables to longer-interval injectables (e.g., ≥ 1 month). Several evidence-based data support
the switching to longer-interval injectables in medically stable patients.
Switching from RLAI to PP1M: In a multicenter, prospective, open-label, 6-month interventional study, PP1M improved
PANSS score by 50% in one-third of non-acute phase patients who remained symptomatic despite prior RLAI therapy [45]. In
another retrospective, longitudinal cohort study comparing the differences in patterns, resources, and costs of healthcare
between patients treated with RLAI and PP1M, PP1M led to lower rates of admission, fewer emergency department visits, and
shorter hospital stay compared with RLAI [77].
Switching from PP1M to PP3M: According to a post-hoc analysis of three randomized controlled trials comparing the
efficacy of oral paliperidone, PP1M, and PP3M, PP3M was associated with later discontinuation and lower risk of relapse
compared with PP1M [18]. Studies have shown that plasma concentrations are still stable after switching from PP1M to PP3M,
and longer-interval long-acting injectable antipsychotics can further improve patient compliance, reduce relapse and
re-admission rates, enhance social functioning, improve the quality of life and alleviate the burden of family members [46-49].
Therefore, some patients may benefit more from timely switching to longer-interval injectables.
Switching from PP3M to Paliperidone Palmitate 6-month (PP6M): According to a 12-month follow-up noninferiority
study in 2022 comparing PP6M and PP3M in the risk of schizophrenia relapse, PP6M was comparable to PP3M in terms of
relapse events during the double-blind period, meeting the criteria for noninferiority [50].
Expert recommendation/experience in terms of intended population and timing of switching long-acting injectables:
Long-acting injectables demonstrate significant clinical value in improving outcomes and compliance as well as reducing
relapse rate in patients, and moreover, longer-interval injectables bring new hope to patients and caregivers. For patients who
plan to use or have started long-acting injectables, the therapy regimen should be developed on the principle of "beginning
with the end in mind", i.e. considering switching to longer-interval long-acting injectables (e.g. ≥ 1 month) after patient
condition is stable with shorter-interval long-acting injectables. Among existing long-acting injectables, if the efficacy is
definite, patient symptoms are stable and the patient/guardian or the physician considers a necessity, longer-interval
long-acting injectables may be used after physician-patient communication; considering that the treatment of schizophrenia
and the change of conditions are influenced by various factors, the patient should be informed to visit the medical institution
regularly, monitor adverse reactions, and adjust the drug therapy regimen or dose timely.
Currently, only PP3M is approved among antipsychotics with a treatment interval of > 1 month in China. Take the
switching from PP1M to PP3M as an example to detail the switching method [78-79]: PP3M can only be used in clinically stable
patients who have received PP1M for at least 4 months; to ensure consistent maintenance dose, the last two doses of PP1M
before the start of PP3M should remain consistent: PP1M 75 mg eq is equal to PP3M 263 mg eq, PP1M 100 mg eq is equal to
PP3M 350 mg eq, and PP1M 150 mg eq is equal to PP3M 525 mg eq; PP3M may be started 7 d before or after the last monthly
administration of PP1M in the regimen (Figure 1).
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PP1M
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±7 d
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1 month

±7 d

1 month

±7 d

3 months

3 months

±7 d

±2 weeks

±2 weeks

Figure 1 Example of converting PP1M to PP3M
3.5 What are the precautions for the use of long-acting injectables in special populations?
[Recommendation]
(1) For elderly patients aged ≥ 65 or patients with liver and kidney damage, the dose should be adjusted based on
their liver and kidney functions according to the package insert (Recommendation grade: C).
(2) None of the long-acting injectables are currently indicated for use in children or adolescents, and pregnant or
lactating women (Recommendation grade: D).
(3) It is recommended that patients with schizophrenia receive COVID-19 vaccine during the stable or
maintenance phase of the disease (Recommendation grade: C).
3.5.1 Elderly patients: For elderly patients, especially those with comorbid physical conditions or on combined use of multiple
drugs, the starting dose should be one-quarter to one-half of the usual starting dose in adults from the perspective of
pharmacokinetics [14].
No differences are found in pharmacokinetic parameters between older (aged ≥ 65) and younger adults (aged 18-64) for
several second-generation long-acting antipsychotics, and therefore no dose adjustment for long-acting injectables is required
among different age groups. Since liver and kidney damages are common in elderly patients, it is recommended to adjust the
therapeutic dose of long-acting injectables based on their liver and kidney functions according to the package insert [9].
The 2021 Expert Consensus on Long-acting Injectables in Taiwan Region recommends the use of long-acting injectables
in elderly patients with schizophrenia. Due to the lack of evidence-based data from high-quality randomized controlled studies,
the risk-benefit ratio of long-acting injectables should be evaluated with caution for use in elderly patients, and a low starting
dose should be selected based on their liver and kidney functions according to the package insert [63].
3.5.2 Adolescents (aged < 18): None of the long-acting injectable antipsychotics are currently indicated for use in children or
adolescents with schizophrenia [9]. Younger patients with first-episode psychosis are possibly more prone to adverse reactions
such as increased body mass and metabolic syndrome, which may affect the initial choice of antipsychotics. Therefore, when
starting with a low dose, this group of patients may be more willing to continue the treatment, with compliance improved [14].
The 2021 Expert Consensus on Long-acting Injectables in Taiwan Region recommends the use of long-acting injectable
antipsychotics in adolescent patients (aged 11-18) with schizophrenia [54-56, 63].
Long-acting antipsychotics may be used as appropriate if clinically necessary after informed consent has been obtained
through adequate communication with the patient/family members.
3.5.3 Pregnant or lactating women: None of the antipsychotics are currently indicated for use in perinatal female patients [9].
For use in pregnant women, antipsychotics should be used at the lowest effective dose in several fractions, and long-acting
injectables are not recommended [15]. In case of high relapse risk of psychiatric symptoms following childbirth, the original
drug therapy should be continued, and those who discontinue the drug should restart the drug therapy [15].
3.5.4 Patients with liver and kidney damage: Currently, there is a lack of evidence for the use of long-acting injectables in
patients with liver and kidney damage, and therefore it is recommended to use them according to the corresponding package
insert.
3.5.5 Recommendations on COVID-19 Vaccine in patients with schizophrenia [80]: It is recommended that all patients with
mental disorders receive the COVID-19 vaccine during the stable and maintenance phases of the disease, and the drug should
not be discontinued or changed spontaneously during vaccination. Patients in the acute phase of mental and/or physical
conditions should receive the COVID-19 vaccine when the condition is stable.
Long-acting injectable antipsychotics, like other oral antipsychotics, will not affect the injection of COVID-19 vaccine.
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The specific requirements are subject to the national regulations on the use of COVID-19 vaccine.
3.6 What are the common adverse reactions and management measures during the use of long-acting injectables?
[Recommendation]
Long-acting injectables have similar adverse reactions to other oral drugs. Prophylaxis is mainly recommended
for various adverse reactions. In case of adverse reactions, the dose reduction, drug switching or symptomatic
treatment may be selected as appropriate. (Recommendation grade: B)
It is also important to monitor the adverse reactions throughout the antipsychotic treatment. Some adverse reactions (e.g.,
sedation and nausea) are significant at the start of treatment but resolve, at least to some extent, following continued treatment.
Some adverse reactions (e.g., hypotension and akathisia) may occur at the start of treatment and worsen with increasing doses.
Some adverse reactions occur only after prolonged treatment (e.g., tardive dyskinesia) or become more significant after the
acute symptoms has been better managed (e.g., sexual dysfunction) [14].
Long-acting injectables generally have similar adverse reactions to other oral drugs, including extrapyramidal adverse
reactions (extrapyramidal symptoms, e.g., acute dystonia, pseudo-Parkinsonism syndrome, akathisia, and tardive dyskinesia),
metabolic syndrome, and hyperprolactinemia [9]. In addition, long-acting antipsychotics may cause injection-related adverse
reactions at the injection site, including pain, swelling, redness or sclerosis [14]. The specific management is as follows.
3.6.1 Management of common extrapyramidal symptoms [9,14]
The management of common extrapyramidal symptoms is described in Table 7.
Table 7 Management of Common Extrapyramidal Symptoms
Extrapyramidal
Prophylaxis
Treatment
Symptoms
Acute dystonia
Recommend the use of drugs Oral or IM anticholinergics for acute dystonia, repeated after
associated
with
fewer 30 min if not relieved by intramuscular injection;
extrapyramidal symptoms; start at a antihistamines; benzodiazepines
low dose and slowly escalate the
dose
Pseudo-Parkinsonism
Recommend the use of drugs Reduce dose; switch to drugs associated with a lower risk of
syndrome
associated with a lower risk of parkinsonian symptoms, such as second-generation
pseudo-Parkinsonism
symptoms antipsychotics;
short-term
combination
with
and slowly escalate the dose
anticholinergics
Akathisia
Recommend the use of drugs Reduce dose; switch to second-generation antipsychotics
associated with less akathisia; associated with fewer adverse effects; use in combination
slowly escalate the dose
with β-blockers (propranolol 30–60 mg/day) as appropriate,
use with caution in patients with bradycardia and associated
contraindications, and use in combination with
anticholinergics or benzodiazepines
Tardive dyskinesia
Recommend the use of drugs Reduce dose; choose either valbenazine or d
associated with less tardive deutetrabenazine; consider the use of Ginkgo biloba extract
dyskinesia, and assess risk factors
or clonazepam
[71]
3.6.2 Metabolic syndrome
The Chinese Guidelines for the Prevention and Treatment of Schizophrenia (Second Edition) propose that all patients
should be assessed for the risk of metabolic syndrome before use of proper antipsychotics. For obese patients or those with
metabolic disorders, drugs with great impact on metabolism should be excluded as far as possible. It is recommended that
patients should regularly monitor body weight, blood glucose and blood lipids, adjust dietary structure and lifestyle, do more
exercise, and switch to another drugs when necessary [15]. The management of metabolic syndrome is described in Table 8.
Table 8 Management of Metabolic Syndrome
Disease
Prophylaxis
Treatment
Increased body mass/obesity Select drugs with little impact on body weight; Lifestyle
intervention
(dietary
regularly monitor changes in body mass; give control, and physical exercise);
warnings when body mass increases by > 7%, and switch to other drugs; add metformin
suggest adjusting the lifestyle and dietary structure
(1,000 mg/d)
Hypertension/Hyperglycemia Select drugs with fewer adverse effects; screen risk Lifestyle
intervention
(dietary
factors affecting blood glucose, and examine fasting control, and physical exercise);
blood glucose and glycosylated hemoglobin; monitor switch to other drugs; take
blood glucose regularly
hypoglycemic drugs if necessary
Dyslipidaemia
Select drugs with fewer adverse effects; screen risk Lifestyle
intervention
(dietary
factors associated with dyslipidaemia, and examine control, and physical exercise);
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switch to other drugs

3.6.3 Hyperprolactinemia [9]
For the treatment of hyperprolactinemia, researchers propose measuring the baseline prolactin level before antipsychotic
treatment for subsequent comparative monitoring. If the prolactin level is higher than the upper limit of normal in the
subsequent treatment, differential screening is required. If other contributing factors to elevated prolactin levels are excluded
and it is determined that hyperprolactinemia is caused by antipsychotics, patients should be treated separately against the
presence of associated clinical symptoms of elevated prolactin levels. If the patient has elevated prolactin levels without
associated clinical symptoms, management is temporarily not needed but close monitoring is required; if the patient present
associated clinical symptoms, it is recommended to manage by referring to the corresponding process. Recommendations for
management of antipsychotic hyperprolactinemia in men [9] are presented in Figure 2. Recommendations for management of
antipsychotic hyperprolactinemia in women [9] are presented in Figure 3.
Before starting or switching: measure baseline PRL
levels
Serum PRL level > upper limit of normal 16.5 ng/ml ± clinical
symptoms
Exclude other causes associated with elevated PRL levels:
elevated macroprolactin levels; other diseases, such as pituitary
diseases, chronic kidney diseases, chest wall injuries/infections,
and hypothyroidism

Symptomatic hyperprolactinaemia and/or PRL > 100
ng/ml
·Sexual dysfunction
·Gynecomastia/lactation
·Male sterility/oligospermia, etc.
·Osteoporosis, acne, etc.

Considerations:
temporal
relationship
between
antipsychotic treatment and
elevated PRL levels, etc.;
endocrinologist consultation is
recommended in case of
unknown cause or positive
pituitary MRI

Asymptomatic hyperprolactinaemia

Regular
monitoring
intervention

without

Clinical symptom monitoring

Interventions
·Reduce the dose of antipsychotics
·Change the antipsychotics being used
·Use in combination with aripiprazole
·Use in combination with metformin
·Use in combination with hormone therapy (e.g., persistent
hypogonadism)

Normal or significantly
reduced PRL levels

PRL level monitoring
·Reassess within 12 months if PRL > 16.5 ng/ml and < 50 ng/ml
·Reassess within 6 months if PRL > 50 ng/ml
·Give intervention, lower prolactin levels, and reassess within 3
months if PRL > 100 ng/ml
·Reassess 3 months after dose increase of antipsychotics
·Reassess if clinical symptoms are present

Birth control (avoid testosterone
therapy if planning to have a child)
Adverse reactions/auxiliary tests
·Bone health: bone mineral density testing in men aged >
50
·Vitamin D and thyroid function tests
·Sex hormone levels

Note: PRL = prolactin
Figure 2 Recommendations for Management of Antipsychotic Hyperprolactinemia in Men
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Before starting or switching: measure baseline PRL
levels
Serum PRL level > upper limit of normal 28.3 ng/ml ± clinical
symptoms
Exclude other causes associated with elevated PRL levels:
elevated macroprolactin levels; other diseases, such as pituitary
diseases, chronic kidney diseases, chest wall injuries/infections,
hypothyroidism; pregnancy/lactation

Symptomatic hyperprolactinaemia and/or PRL > 100
ng/ml
·Sexual dysfunction
·Amenorrhea or menoxenia, infertility
·Galactorrhoea
·Osteoporosis, acne, hirsuitism, etc.

Considerations:
temporal
relationship
between
antipsychotic treatment and
elevated PRL levels, etc.;
endocrinologist consultation is
recommended in case of
unknown cause or positive
pituitary MRI

Asymptomatic hyperprolactinaemia

Regular
monitoring
intervention

without

Clinical symptom monitoring, especially
menstrual cycle
Interventions
·Reduce the dose of antipsychotics
·Change the antipsychotics being used
·Use in combination with aripiprazole
·Use in combination with metformin
· Use in combination with hormone therapy (e.g.,
persistent hypogonadism)

Normal or significantly
reduced PRL levels

PRL level monitoring
·Reassess within 12 months if PRL > 16.5 ng/ml and < 50 ng/ml
·Reassess within 6 months if PRL > 50 ng/ml
·Give intervention, lower prolactin levels, and reassess within 3
months if PRL > 100 ng/ml
·Reassess 3 months after dose increase of antipsychotics
·Reassess if clinical symptoms are present

Birth control (avoid testosterone
therapy if planning to have a child)
Adverse reactions/auxiliary tests
·Menstrual cycle: breast examination
·Bone health (bone mineral density during amenorrhea or
menopause)
·Vitamin D and thyroid function tests
·Sex hormone levels

Figure 3 Recommendations for Management of Antipsychotic Hyperprolactinemia in Women
3.6.4 Injection-related adverse reactions
Causes of redness, swelling and induration due to injection: improper injection site; thick subcutaneous fat, loose tissue
and poor contractility in obese patients; insufficient injection depth, only into the subcutaneous tissue or sarcolemma, not
reaching the muscle, thus resulting in malabsorption.
Proper injection method (taking PP1M and PP3M as examples): (1) Pre-injection shaking: Shake PP1M for at least 10 s,
and shake PP3M more vigorously for at least 15 s; (2) Needle selection: Select needles according to the injection site/body
weight, and do not mix the needles for PP1M and PP3M; (3) Injection into deep muscle: Slowly inject into the deep muscle,
and do not inject into the blood vessels or subcutaneous tissue; (4) Injection at one time: Inject PP1M and PP3M at one time
instead of in several fractions.
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Recommendations for management of local pain, redness, swelling and other adverse reactions: (1) Local irradiation
with a specific electromagnetic spectrum treatment radiator, twice daily, 30 min/time; wash a piece of fresh ginger, remove
ginger peel, cut into small slices with a thickness of 1 cm, and gently rub the injection site with the slices in a circling way, 2–
3 min/time, 2–3 times daily. Be careful not to rub with force to avoid skin injury. Stop applying it temporarily in case of
obvious symptoms of local infection. Do not use old ginger to avoid irritating the skin. (2) Wet compress the affected area with
hot vinegar, 30 min/time. (3) Cut fresh potatoes into thin slices, and apply them to the indurated surface. (4) After 2–3 h, hot
compress can relax muscles, facilitate needle insertion, and dilate local blood vessels.
Studies have shown that the adverse reactions of long-acting injectables tend to be gradually alleviated over time.
Therefore, if patients experience tolerable adverse reactions at the early stage of using long-acting injectables, the symptoms
can be alleviated by appropriate treatment. The adverse reactions may be gradually reduced over time, and the dose of
corresponding therapeutic drugs can be reduced or discontinued [81].
During community follow-up, patients should be referred to a psychiatric hospital in case of symptoms or adverse
reactions that cannot be managed or explained.
3.7 What are the management measures for symptom fluctuations during the use of long-acting injectables?
Recommendation
For symptom fluctuations during the use of long-acting injectable, the potential influencing factors of symptom
fluctuations should be explored firstly, and then corresponding countermeasures should be taken against the causes.
(Recommendation grade: C)
Symptom fluctuations may occur during the use of any antipsychotics due to various factors, such as incorrect diagnosis,
psychosocial stress, and withdrawal of the previous drug.
The 2020 expert consensus on long-acting injectables in China sorts out the causes as follows, and recommends that if
the patient experiences symptom fluctuations during the use of long-acting injectables, the potential influencing factors
should be explored firstly, and then the corresponding countermeasures should be taken against the factors [9], as shown in
Table 9.
Table 9 Potential Influencing Factors and Countermeasures of Symptom Fluctuation in the Use of Long-acting Injection
Potential
Influencing Factors

Possible Problems

Countermeasures

Diagnostic
accuracy

Whether
the
diagnosis
schizophrenia is accurate

Other comorbidities

Whether the patient suffers from other Consider the impact of other comorbidities on the efficacy of
comorbidities and is taking other long-acting injectables and the possible drug-drug
drugs
interactions

Psychosocial
factors

Whether
there
is
dependence or abuse

of Carefully assess the diagnosis

substance Deal with substance dependence/abuse
psychological education/support

and

give

Whether there are recent changes in Psychotherapy
daily life/trauma/stress
Use of long-acting
injectables

Time and method of initiation of Use long-acting injectables according to the corresponding
long-acting injectables (loading dose, package insert
and concomitant oral medications)
Whether the long-acting injectables The storage and usage of long-acting injectables should meet
are used properly (including the the requirements in the package insert
injection site/needle selection/shaking
adequacy)
Injection time/dose of last long-acting In case of a missed dose of long-acting injectable, take it as
injectable
soon as possible according to the package insert
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Number of
fluctuations

times

of

symptom Increase the dose of long-acting injectables or shorten the
interval between injections

Adverse reactions
of
long-acting
injectables

Whether the clinical symptom Assess the current symptoms and adverse reactions,
fluctuations are exacerbations or including the nature, occurrence time and severity; manage
relapses, or adverse drug reactions
the adverse reactions symptomatically

Withdrawal of the
previous drug

Whether the clinical symptom Evaluate the current symptoms and adverse reactions,
fluctuations are exacerbations or including the nature, occurrence time and severity; manage
relapses, or withdrawal reactions
the withdrawal reactions symptomatically, or restart the
previous drug and withdraw it slowly as appropriate

3.8 What are the principles and precautions for combination therapy during the use of long-acting injectables?
[Recommendation]
(1) Monotherapy is recommended for the treatment of schizophrenia, and combined therapy is used only in
specific and limited clinical cases. (Recommendation grade: A)
(2) For patients with schizophrenia who have concomitant medications, control of psychiatric symptoms,
comorbidities, and efficacy, safety and tolerability should be considered for the use of long-acting injectables.
(Recommendation grade: B)
Guidelines on schizophrenia generally recommend the use of combination therapy only in specific and limited clinical
cases. However, combination therapy is relatively common in clinical practice. A retrospective study in Japan in 2022 found
that only one-third of patients with schizophrenia were treated with a combination of second-generation long-acting
injectables and oral antipsychotics, corroborating the universality of combination therapy in the real world

[57]

; in addition,

researchers emphasized the necessity of monitoring the patients' compliance with oral drugs in combination with long-acting
injectables [57].
According to study reports, the main purpose for clinicians to choose combination therapy is to control positive
symptoms. It is also applied to alleviate negative symptoms, improve cognitive function, reduce re-admission, treat specific
comorbidities such as depression and anxiety, reduce the overall dose of antipsychotics, and antagonize adverse reactions.
However, it is associated with the risk of increased adverse reactions or healthcare costs [58].
The use of long-acting injectables does not mean that oral drugs are not used at all. A small number of patients may
require oral administration of low-dose antipsychotics combined with full-dose long-acting injectables to improve the
symptoms with better experience.
The 2020 APA guideline recommends the synergistic therapy with an antidepressant + an antipsychotic in patients with
negative or depressive symptoms; benzodiazepines, such as lorazepam, may be used in patients with catatonia; dose
adjustment of only one of the drugs is recommended at a time, if required (therapeutic benefit or side effect) during the
combined therapy; moreover, if patients experience worse symptoms on drug therapy at fixed doses, it is necessary to adjust
the existing treatment regimen instead of simply adding drugs to the existing treatment regimen [14].
The 2021 guideline of Japan states that the combination with antipsychotics may be more efficacious than monotherapy,
but its impact remains unclear and it may bring more adverse reactions (C); in case of relapse, the cause of relapse should be
identified first prior to antipsychotic combined therapy (2C) [61].
According to the recommendation by the 2020 expert consensus on long-acting injectables in China, 73.3% of experts
agree that the long-acting injectables should be used alone; if there is a necessity for combination with oral antipsychotics due
to symptom fluctuations and other reasons, it is recommended that before starting the combination, patients should be
comprehensively evaluated to identify the main symptoms requiring intervention, so as to select proper combined drugs. The
following should be considered: the efficacy and safety of combined drugs on target symptoms, patient's tolerance, and
interdrug interaction between combined drugs and long-acting injectables currently being used, all of which should be closely
evaluated. If combination therapy is still required when long-acting injectables are given at the highest dose, plasma
concentrations should be monitored before/during combination [9].
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If patients require oral administration of other drugs due to other acute and chronic diseases such as hypertension and
diabetes, or comorbidities such as depression, agitation and sleep disorders, interdrug interactions should be fully considered
to avoid treatment failure or serious adverse reactions due to significantly impaired efficacy and safety caused by interdrug
interactions [52].
Generally, such important adjustments to treatment regimen should be made under the guidance of a specialist. The
community health workers should refer the patient to a mental health center timely, during which the physicians should
observe the changes in the patient's condition after regimen adjustment and communicate with the specialist and family
members in a timely manner.
3.9 Under what circumstances do community mental health workers need support from psychiatrists?
[Recommendation]
It is recommended that patients with acute episodes of schizophrenia, agitation/aggression, or other
unmanageable adverse reactions should be referred to a specialized hospital in a timely manner. (Recommendation
grade: C)
Compared with specialized hospitals, communities have such objective limitations as lack of experience, and insufficient
personnel and equipment. Therefore, efforts to maintain unobstructed communication with specialized hospitals and establish
a smooth referral channel and mechanism are crucial to the management of schizophrenia in communities.
Patients with schizophrenia in the community should be referred in a timely manner according to clinical experience in
case of the following conditions

[82]

: (1) acute-phase schizophrenia; (2) excitement, impulsivity, hurting others and

self-hurting, which threatens the personal and property safety of themselves and surrounding communities; (3) suicidal
ideation and behavior; (4) relapse and aggravation of symptoms, or refusal of treatment during maintenance treatment in the
community; (5) it is difficult to maintain treatment at home in case of adverse drug reactions; (6) patients and their family
members are reluctant to receive treatment in the community.
Timely referral can greatly reduce the difficulty of patient management in the community, improve the efficiency of
diagnosis and treatment, alleviate the symptoms of patients as soon as possible, and reduce the burden on family members and
social management.
3.10 What are the main points the community mental health workers should convey when recommending long-acting
injectables for patients?
[Recommendation]
In the process of physician-patient communication, reasonable introduction of relevant information on the
benefits and tolerability of long-acting injectables is helpful to establish patient's confidence in long-acting injectables.
(Recommendation grade: C)
KANE et al.

[53]

recently conducted a study investigating long-acting injectables in patients with early-phase

schizophrenia in mental health clinics in multiple communities in the United States. The study screened 576 patients during
the enrollment period, only 14.4% clearly refused to receive long-acting injectables and most of them were willing to receive
long-acting injectables. This study suggested that effective communication helps to improve patient's acceptance of
long-acting injectables.
For community mental health workers, the key to effective communication is stable cooperation with patients and their
family members. When specialists establish a "physician-patient alliance" with patients and their family members, community
mental health workers, as the front-line healthcare workers in communities, should also join the alliance. For the changes in
patients' conditions, and the development and modification of treatment regimens, the monitoring of patients at home and
other factors should be fully understood, and smooth communication with their family members and a cooperation
relationship of mutual trust should be maintained, so that patients and their family members can seek help in case of an
emergency.
When communicating with patients and their family members about long-acting injectables, community mental health
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workers should focus on the following four aspects: (1) Establishing patients/family members' confidence in long-acting
injectables: Long-acting injectables are generally esterified from antipsychotics and are a major breakthrough in the treatment
of mental illness, which can slowly release active pharmaceutical ingredients for a long time to maintain stable plasma
concentrations, thereby ensuring treatment compliance [11]. The first-generation long-acting injectable antipsychotics have
been available for more than 60 years, and the second-generation long-acting injectable antipsychotics have been introduced
into clinical practice for 20 years [11], and more patients benefit from long-acting injectables; (2) Benefits to patients: A wide
range of data show that long-acting injectables can significantly alleviate symptoms, reduce the risk of admission, delay
relapse, and minimize the risk of relapse for a long time even after drug discontinuation

[16-18,31,33]

; (3) Benefits to family

members: Early use of long-acting injectables helps to reduce re-admission rates and healthcare costs, and increase
employment rates

[39]

. Relevant national policies support the use of long-acting injectables in the community. Long-acting

dosage forms have been successively included in the National Reimbursement Drug List, and drug costs have been
significantly reduced after health insurance negotiation and medical insurance reimbursement; (4) Sharing successful cases
and building patients' confidence in long-acting injectables.
4

Summary and Vision
With the increasing use of long-acting injectable antipsychotics in the community, problems related to the use of

long-acting injectables in the management of schizophrenia in the community are increasingly frequently. Compared with
common oral antipsychotics, long-acting injectables have their unique merits such as improving compliance and reducing
management burden, meeting the management needs in the community. However, there are higher requirements for the
professional skills of community mental health workers and managers in terms of the use and management of long-acting
injectables. With the advancement of preparation technologies, more long-acting injectables and longer-interval injectables
(e.g., PP6M) will be introduced into the community to benefit physicians and patients to a large extent.
This Expert Consensus upholds the original aspiration to help community mental health workers effectively use
long-acting injectables to benefit more patients with schizophrenia. However, due to complex clinical challenges, it is
recommended that psychiatric experts and front-line community mental health workers actively propose suggestions and
opinions for the supplement and revise of the consensus, and collect new clinical challenges in the future, so as to flesh out and
update the consensus.
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